基于ICH E6(R3)指导原则的制药企业临床试验数据治理实施策略OA

In 2025,the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use(ICH)released the final version of E6(R3):Guideline for Good Clinical Practice,which establishes data governance as an independent chapter and restructures the global clinical trial data management framework based on the concepts of Quality by Design(QbD)and Risk-Based Quality Management(RBQM).The National Medical Products Administration(NMPA)has announced that the ICH E6(R3)guideline will apply to all clinical trials initiated after March 31,2026.Facing challenges in the implementation of this guideline among domestic pharmaceutical enterprises,including conceptual misalignment,insufficient business adaptation,unclear role transformation,and lack of standardized procedures for newly introduced processes,this paper draws on practical experience from nearly 100 domestic and international multicenter clinical trials.It systematically analyzes the historical evolution and global innovation logic of the guideline,and focuses on three key modules:blinding maintenance(including randomization),data life cycle management,and computerized system validation(CSV).Common operational gaps and key risk control priorities are also summarized.Furthermore,this study proposes a four-dimensional implementation framework encompassing documentation,systems,processes,and risk management.Differentiated implementation strategies are designed for enterprises of different scales and project types,and compliance transition rules between ongoing and newly initiated projects are clarified.It also provides a dedicated audit trail review(ATR)scheme,key role adjustment requirements,and a system assurance mechanism characterized as monitorable,auditable,and optimizable are proposed.By establishing a closed-loop framework from conceptual interpretation and problem identification to implementation pathway design and assurance mechanisms,this paper aims to provide pharmaceutical enterprises with practical and compliant guidance,thereby supporting Chinese innovative drugs in overcoming international regulatory barriers and accelerating global development.